Tessera
Folgen

MRC Weatherall Institute of Molecular Medicine

@imm.ox.ac.uk

The MRC WIMM is a research institute at the University of Oxford with 5 core research areas: rare diseases, haematology, immunology and infection, stem cells and developmental biology and cancer biology. www.imm.ox.ac.uk

513 Posts599 Follower141 Folgt
MRC Weatherall Institute of Molecular Medicine@imm.ox.ac.uk · 6d ago

#WIMMReads🧪 Ahmed Group's early access study identifies specialised immune cells in the fallopian tube that may help detect #OvarianCancer at its earliest stages. Findings could inform future immunotherapies and prevention strategies. #AcademicSky 

Transcriptomic analysis of tissue-resident memory T cells of the fallopian tube reveals a precursor immune surveillance network for ovarian cancer prevention - Nature Communications

High-grade serous ovarian cancers (HGSC) are refractory to immunotherapy, and a comprehensive characterization of the immune landscape at these lesions is lacking. Here, the authors employ single-cell RNA and TCR sequencing of patient-derived tissues to characterize T cell clonality and differentiation during tumor evolution. Tissue-resident memory-like T cells in early lesions display tumor reactivity, exhibit reduced exhaustion, and are implicated in early immune surveillance, and could be leveraged for the design of immunomodulatory therapeutic approaches.

nature.com

MRC Weatherall Institute of Molecular Medicine@imm.ox.ac.uk · last wk.

We’re delighted to welcome sixth form students from state schools across Oxfordshire for our 2026 Work Experience Programme! 👋 Today kicked off with Karen’s induction session. Over the next two weeks, students will explore our labs, meet our researchers and discover what life at WIMM is all about. 🧬

Bild
MRC Weatherall Institute of Molecular Medicine@imm.ox.ac.uk · 2w ago

#WIMMReads 🧪 From the Claus Nerlov Group: researchers identify a new set of markers that enables accurate isolation of platelet biased blood #StemCells, opening new opportunities to study ageing, blood cancers, and blood formation. #Haematology #AcademicSky @rdm.ox.ac.uk @medsci.ox.ac.uk

Multiome-based identification of molecular markers for prospective identification of platelet-biased HSCs

Here, Zhang et al. identify a transgene-independent marker combination that prospectively isolates platelet-biased hematopoietic stem cells with high purity, overcoming a key limitation in the field, ...

cell.com

MRC Weatherall Institute of Molecular Medicine@imm.ox.ac.uk · 3w ago

#WIMMReads🧪 From the Chapman Group: a new preprint offers a potential explanation for why ATM deficient cancers respond to PARP inhibitors, with implications for cancer treatment and Ataxia Telangiectasia. #CancerResearch #AcademicSky @rdm.ox.ac.uk @medsci.ox.ac.uk @rosschapmanlab.bsky.social 🧬

ATM safeguards DNA replication at endogenous base lesions

Poly(ADP-ribose) polymerase inhibitors (PARPi) exploit homologous recombination deficiency (HRD) in BRCA1/2-mutated cancers to induce synthetic lethality[1][1]–[3][2]. PARPi also kill cancer cells lac...

doi.org

MRC Weatherall Institute of Molecular Medicine@imm.ox.ac.uk · 4w ago

A major new pan European initiative is set to transform how scientists identify and target cancer’s weaknesses and our very own Sumana Sharma is one of its founding partners. 🧪 The project aims to predict cancer vulnerabilities before they are experimentally tested.👇 @rdm.ox.ac.uk @medsci.ox.ac.uk

Beyond cancer dependency maps: the PRECISE vision

Dr Sumana Sharma is one of the founding partners of a major new pan-European initiative that aims to transform how scientists identify and target cancer's weaknesses, moving beyond simply mapping canc...

imm.ox.ac.uk

MRC Weatherall Institute of Molecular Medicine@imm.ox.ac.uk · 4w ago

#WIMMReads 🧪 From the Peter McHugh Group: a new study reveals how mutations in the proteins CDIN1 and Codanin 1 disrupt an RNA cutting enzyme complex, providing new insight into the rare blood disorder Congenital Dyserythropoietic Anaemia type I. #Haematology #RareDisease #AcademicSky

CDIN1-Codanin-1 complex defective in congenital dyserythropoietic anaemia type I is an RNA nuclease - Nature Communications

Congenital dyserythropoietic anaemia type I is caused by mutations in CDAN1 or CDIN1, but the molecular basis of disease is unclear. Here, the authors show that Codanin-1 and CDIN1 form an RNA nucleas...

doi.org

MRC Weatherall Institute of Molecular Medicine@imm.ox.ac.uk · last mo.

🌿 Congratulations to the WIMM #GreenImpact team on achieving Gold in the University of Oxford’s 2026 Green Impact Awards! Thank you to everyone whose commitment is helping make our Institute a more sustainable place to work and do research. 🧪 @rdm.ox.ac.uk @ox.ac.uk @medsci.ox.ac.uk #AcademicSky

MRC WIMM achieves Gold Green Impact award

Congratulations to the Institute's Green Impact team, who achieved Gold in the University of Oxford's 2026 Green Impact awards.

imm.ox.ac.uk

MRC Weatherall Institute of Molecular Medicine@imm.ox.ac.uk · last mo.

#WIMMReads🧪 A collaboration between the #MRCWIMM and UCL presents a #CARTCellTherapy that selectively targets CALR mutated blood cancer cells while sparing healthy stem cells. #BloodCancer #AcademicSky @bethpsaila.bsky.social @rdm.ox.ac.uk @medsci.ox.ac.uk

New personalised therapy targets chronic blood cancer

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving hea...

imm.ox.ac.uk

Oxford Medical Sciences Division@medsci.ox.ac.uk · last mo.

NEWS: Oxford researchers awarded ARIA funding to develop transformative anti-viral therapies @ndm.ox.ac.uk @ndorms.bsky.social @kiroxford.bsky.social @rdm.ox.ac.uk @imm.ox.ac.uk

Oxford researchers awarded ARIA funding to develop transformative anti-viral therapies

Three innovative research projects aimed at transforming how we protect against respiratory viruses, led by teams at the University of Oxford, have secured funding through the UK’s Advanced Research and Invention Agency (ARIA).

medsci.ox.ac.uk

MRC Weatherall Institute of Molecular Medicine@imm.ox.ac.uk · last mo.

We’re delighted to share that a research project led by #MRCWIMM Prof Jan Rehwinkel is one of three innovative Oxford led projects that have secured funding through ARIA. (@aria-research.bsky.social). #WIMMHighlights #AcademicSky 🧪 @rdm.ox.ac.uk @medsci.ox.ac.uk @ox.ac.uk 🧬

Jan Rehwinkel receives funding to tackle viral threats

A research project led by Professor Jan Rehwinkel is one of three innovative Oxford-led projects aimed at transforming how we protect against respiratory viruses, which have secured funding through th...

imm.ox.ac.uk